Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2025 List of America's Most Successful Mid-Cap Companies
January 23 2025 - 8:03AM
Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq:
CPRX) today announced its inclusion in Forbes' esteemed list of
America's Most Successful Mid-Cap Companies for the year 2025.
Catalyst has ranked an impressive fifth out of 100 companies on the
list.
Last year Catalyst was ranked fourth in Forbes’
list of America’s Most Successful Small-Cap Companies, with this
year’s ranking recognizing the company’s continued growth. The top
100 ranking is based on earnings growth, sales growth, return on
equity and total stock return for the last five years, with more
weight given to the latest year’s data in the ranking. All data is
as of November 27, 2024, according to Forbes.
“Being ranked fifth on the Forbes list of
America’s Most Successful Mid-Cap Companies for 2025 is a testament
to the success of our growth and investment strategy,” said Rich
Daly, President and Chief Executive Officer, Catalyst. “Our
employees are dedicated to helping patients live healthier lives,
and we look forward to continuing our efforts to create value for
our employees, patients and shareholders.”
To create the list, Forbes used data from
FactSet to screen more than 700 companies with a market value
between $2 billion and $10 billion and only considered companies
that also had positive sales growth over the past 12 months and a
share price of at least $5. Financial institutions, REITs,
utilities and limited partnerships were excluded, as were companies
that have been public for less than one year.
About Catalyst
PharmaceuticalsCatalyst Pharmaceuticals, Inc. (Nasdaq:
CPRX) is a biopharmaceutical company committed to improving the
lives of patients with rare diseases. With a proven track record of
bringing life-changing treatments to the market, we focus on
in-licensing, commercializing, and developing innovative therapies.
Guided by our deep commitment to patient care, we prioritize
accessibility, ensuring patients receive the care they need through
a comprehensive suite of support services designed to provide
seamless access and ongoing assistance. Catalyst maintains a
well-established U.S. presence while actively seeking to expand its
global commercial footprint through strategic partnerships.
Catalyst, headquartered in Coral Gables, Fla., was recognized as
one of North America's Fastest-Growing Companies on the 2024
Deloitte Technology Fast 500™ List.
For more information, please visit Catalyst's
website at www.catalystpharma.com.
Forward-Looking StatementsThis
press release contains forward-looking statements, as that term is
defined in the Private Securities Litigation Reform Act of 1995.
Forward-looking statements involve known and unknown risks and
uncertainties, which may cause Catalyst's actual results in future
periods to differ materially from forecasted results. A number of
factors, including those factors described in Catalyst's Annual
Report on Form 10-K for the fiscal year 2023 and its subsequent
filings with the U.S. Securities and Exchange Commission ("SEC"),
could adversely affect Catalyst. Copies of Catalyst's filings with
the SEC are available from the SEC, may be found on Catalyst's
website, or may be obtained upon request from Catalyst. Catalyst
does not undertake any obligation to update the information
contained herein, which speaks only as of this date.
Source: Catalyst Pharmaceuticals, Inc.
Investor Relations Contact:
Mary Coleman, Catalyst Pharmaceuticals, Inc.
(305) 420-3200
mcoleman@catalystpharma.com
Media Contact:
David Schull, Russo Partners
(858) 717-2310
david.schull@russopartnersllc.com
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Historical Stock Chart
From Jan 2025 to Feb 2025
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Historical Stock Chart
From Feb 2024 to Feb 2025